StartupWiki is a community-driven AI-powered research directory of global startup ventures. Explore in-depth profiles of AI, Biotech, CleanTech, FinTech, Cybersecurity, and other deep-tech startups with funding data, financial metrics, competitive analysis, and team insights.
Browse categories: AI & Machine Learning, FinTech, Biotech, Cybersecurity, CleanTech, Quantum Computing, and more.
Browse all startups A-Z for the complete directory.
Read our blog for startup insights and deep dives.
The DeepMind spin-out building an AI drug design engine — backed by $2.7B+ and Big Pharma deals
HQ: London, United Kingdom | Founded: 2021 | Employees: ~200 (2026, est.) | Stage: Late Stage VC (Series B) | Website: https://www.isomorphiclabs.com
Isomorphic Labs was founded in November 2021 as an independent company spun out of Google DeepMind, with DeepMind CEO Demis Hassabis as founder and CEO. Its mission is deliberately grand: use computational AI to rethink drug discovery from first principles — rather than merely accelerate existing workflows. The company builds IsoDDE (Isomorphic Drug Design Engine), a suite of AI models that design, predict, and optimize molecules across the drug discovery pipeline, from target understanding to candidate molecules.\n\nIsomorphic's breakthrough moment for credibility came in January 2024 when it announced landmark partnerships with Eli Lilly and Novartis — deals structured around R&D funding plus success-based milestones that analysts estimated could be worth up to ~$3B combined. The company
Browse: Home | Blog | About | All Startups A-Z | View full profile on StartupWiki